November 29 (SeeNews) - Bulgarian drug maker Sopharma [BUL:SFA] said on Monday that its consolidated net profit rose to 50.5 million levs ($29.2 million/25.8 million euro) in the first nine months of 2021 from 21.9 million levs in the same period of last year.
Sopharma's business generated 1.2 billion levs in revenue in January-September, up from a little over 1 billion levs in the comparable period of 2020, the company said in an interim financial statement.
The drug maker's expenses grew to over 1.1 billion levs from 1 billion levs, mostly due to higher balance cost of sold assets and higher expenses for salaries.
On Monday, shares in Sopharma closed 0.47% lower at 4.28 levs on the Bulgarian Stock Exchange.
Sopharma owns nine production facilities in Bulgaria and has a portfolio of over 200 products. At the end of September 2021, the company employed 1,797 people.
(1 euro = 1.95583 levs)